The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs of the drug.
The second phase 3 trial for Biogen's aducanumab failed to meet its primary and secondary endpoints in 2019.
Biogen plummeted 32% on Monday after the FDA Advisory Committee signalled that it is unconvinced Biogen’s Alzheimer’s therapy is effective in combating the disease. On Friday, the FDA AdCom voted 8-1 that data from the phase 3 EMERGE study evaluating Biogen’s aducanumab in patients with mild Alzheimer’s disease was not […]
Morgan Stanley on Monday upgraded Biogen from underweight to overweight – a rare double upgrade – citing compelling risk versus reward in the long-term. The firm also boosted its price target on Biogen to $US357 from $US263. The new target price represents a more than 30% upside from where Biogen […]
Shares of Biogen surged more than 40% on Tuesday morning after the company announced plans to seek approval for an experimental Alzheimer’s treatment called aducanumab. Investors welcomed the news after the company’s shares plummeted 29% in March when Biogen said it would abandon the therapy following two failed clinical trials. […]
Biogen is surging almost 15% Friday morning. The company’s final analysis of its Alzheimer’s drug, BAN2401, was positive. Patients are showing encouraging results. Watch Biogen trade in real time here. Biogen is surging Friday morning, up 14.47%, after a final analysis of its Alzheimer’s drug, BAN2401, showed positive results. A […]